Expectations trend
FY2028 · fiscal year ending 2028-04-24 · fmp
MiniMed Group, Inc. (MMED)
NASDAQHealth CareMedical - Equipment & ServicesSnapshot 2026-11-04
$18.16-5.86%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Equipment & ServicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.
Next-FY EPS estimate change · 30 days
0.65 → 0.71 EPS · FY ending Apr 24, 2028 · 7 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 5 to 7; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for MMED yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Achieve positive free cash flow | A supporting condition in MiniMed Group, Inc.'s published investment case. The stated target is >=0. | Broken | free cash flow remains negative next fiscal year | Free cash flow: $-90M FY2026-Q1; GAAP. Published target: >=0. Annual target cannot be compared with a quarterly or TTM observation. Sep 8, 2026-90,000,000 USD · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-04-24 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a growth-focused healthcare business with execution and sector risks, rather than a proven durable compounder. The long-term thesis is intact, though evidence is limited and management execution is assessed as neutral overall.
The valuation evidence is mixed: one measure describes MMED as cheap versus peers, while another shows a 48% premium to peers. The model has low confidence, and the expectations gap is negative, so the evidence does not give a clear picture of what the market assumes.
In the latest reported quarter, revenue rose from $723 million to $843 million year over year, with growth in both U.S. and international sales. New-pump sales also grew, and management reported pipeline milestones, although progress on innovation was assessed as mixed. Near-term earnings remain uncertain given a record of misses and erratic surprises, despite a recent reported earnings beat.
Over the next few quarters, continued sales growth and delivery on product launches and pipeline milestones would support the multi-year view. A weakening jobs trend could weigh on cyclical healthcare names, while continued earnings strength from sector bellwether FONR could sustain sector momentum; misses or lower guidance from FONR could weaken that support.
The 1-to-3-year thesis remains intact, but MMED is loss-making and the evidence is low-confidence, with near-term execution and sector conditions still important. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in MiniMed Group, Inc.'s published investment case. The stated target is >=0. |
| Improving |
| operating income remains negative next fiscal year |
Operating income: $5M FY2027-Q1; GAAP. Published target: >=0. Annual target cannot be compared with a quarterly or TTM observation. Sep 8, 20265,000,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve at least 10% revenue growth | A primary condition in MiniMed Group, Inc.'s published investment case. The stated target is >=10% YoY. | Intact | falls below 10% revenue growth next fiscal year | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.69 → $0.71 · observed estimates
$3.70B → $3.72B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-08-27 | $0.69 | $3,699,351,046 | 5 / 10 |
| 2026-08-28 | $0.69 | $3,699,351,046 | 5 / 10 |
| 2026-08-29 | $0.69 | $3,699,351,046 | 5 / 10 |
| 2026-08-30 | $0.69 | $3,699,351,046 | 5 / 10 |
| 2026-08-31 | $0.69 | $3,699,351,046 | 5 / 10 |
| 2026-09-01 | $0.69 | $3,699,351,046 | 5 / 10 |
| 2026-09-02 | $0.66 | $3,706,449,853 | 5 / 10 |
| 2026-09-03 | $0.66 | $3,712,329,728 | 6 / 10 |
| 2026-09-04 | $0.66 | $3,712,329,728 | 6 / 10 |
| 2026-09-05 | $0.66 | $3,712,329,728 | 6 / 10 |
| 2026-09-06 | $0.66 | $3,712,329,728 | 6 / 10 |
| 2026-09-07 | $0.66 | $3,712,329,728 | 6 / 10 |
| 2026-09-08 | $0.66 | $3,712,329,728 | 6 / 10 |
| 2026-09-09 | $0.66 | $3,712,329,728 | 6 / 10 |
| 2026-09-10 | $0.66 | $3,712,496,395 | 6 / 10 |
| 2026-09-11 | $0.66 | $3,712,496,395 | 6 / 10 |
| 2026-09-12 | $0.66 | $3,712,496,395 | 6 / 10 |
| 2026-09-13 | $0.66 | $3,712,496,395 | 6 / 10 |
| 2026-09-14 | $0.66 | $3,712,496,395 | 6 / 10 |
| 2026-09-15 | $0.66 | $3,712,496,395 | 6 / 10 |
| 2026-09-16 | $0.65 | $3,712,239,150 | 5 / 9 |
| 2026-09-17 | $0.65 | $3,712,239,150 | 5 / 9 |
| 2026-09-18 | $0.65 | $3,712,239,150 | 5 / 9 |
| 2026-09-19 | $0.65 | $3,712,239,150 | 5 / 9 |
| 2026-09-20 | $0.65 | $3,712,239,150 | 5 / 9 |
| 2026-09-21 | $0.65 | $3,712,239,150 | 5 / 9 |
| 2026-09-22 | $0.65 | $3,710,539,184 | 5 / 9 |
| 2026-09-23 | $0.65 | $3,710,539,184 | 5 / 9 |
| 2026-09-24 | $0.65 | $3,710,539,184 | 5 / 9 |
| 2026-09-25 | $0.65 | $3,714,494,252 | 5 / 9 |
| 2026-09-26 | $0.65 | $3,714,519,252 | 5 / 10 |
| 2026-09-27 | $0.65 | $3,714,519,252 | 5 / 10 |
| 2026-09-28 | $0.65 | $3,714,519,252 | 5 / 10 |
| 2026-09-29 | $0.65 | $3,714,519,252 | 5 / 10 |
| 2026-09-30 | $0.65 | $3,714,519,252 | 5 / 10 |
| 2026-10-01 | $0.65 | $3,714,519,252 | 5 / 10 |
| 2026-10-02 | $0.65 | $3,714,352,585 | 5 / 10 |
| 2026-10-03 | $0.65 | $3,714,352,585 | 5 / 10 |
| 2026-10-04 | $0.65 | $3,714,352,585 | 5 / 10 |
| 2026-10-05 | $0.65 | $3,714,352,585 | 5 / 10 |
| 2026-10-06 | $0.65 | $3,714,352,585 | 5 / 10 |
| 2026-10-07 | $0.68 | $3,714,352,585 | 5 / 10 |
| 2026-10-08 | $0.68 | $3,714,352,585 | 5 / 10 |
| 2026-10-09 | $0.68 | $3,714,352,585 | 5 / 10 |
| 2026-10-10 | $0.68 | $3,714,352,585 | 5 / 10 |
| 2026-10-11 | $0.68 | $3,714,352,585 | 5 / 10 |
| 2026-10-12 | $0.68 | $3,714,352,585 | 5 / 10 |
| 2026-10-13 | $0.70 | $3,713,272,386 | 5 / 11 |
| 2026-10-14 | $0.71 | $3,720,877,931 | 5 / 11 |
| 2026-10-15 | $0.71 | $3,720,713,646 | 6 / 11 |
| 2026-10-16 | $0.71 | $3,720,713,646 | 6 / 11 |
| 2026-10-17 | $0.71 | $3,720,713,646 | 6 / 11 |
| 2026-10-18 | $0.71 | $3,720,354,475 | 7 / 12 |
| 2026-10-19 | $0.71 | $3,720,354,475 | 7 / 12 |
| 2026-10-20 | $0.71 | $3,720,354,475 | 7 / 12 |
| 2026-10-21 | $0.71 | $3,720,354,475 | 7 / 12 |
| 2026-10-23 | $0.71 | $3,720,354,475 | 7 / 12 |
| 2026-10-24 | $0.71 | $3,720,354,475 | 7 / 11 |
| 2026-10-25 | $0.71 | $3,720,354,475 | 7 / 11 |
| 2026-10-26 | $0.71 | $3,720,354,475 | 7 / 11 |
| 2026-10-27 | $0.71 | $3,720,354,475 | 7 / 11 |
| 2026-10-28 | $0.71 | $3,720,354,475 | 7 / 11 |
| 2026-10-29 | $0.71 | $3,720,354,475 | 7 / 11 |
| 2026-10-30 | $0.71 | $3,720,354,475 | 7 / 11 |
| 2026-10-31 | $0.71 | $3,720,354,475 | 7 / 11 |
| 2026-11-01 | $0.71 | $3,720,354,475 | 7 / 11 |
| 2026-11-02 | $0.71 | $3,720,354,475 | 7 / 11 |
| 2026-11-03 | $0.71 | $3,720,354,475 | 7 / 11 |
| 2026-11-04 | $0.71 | $3,720,354,475 | 7 / 11 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 12 Buy / Strong Buy · 3 Hold · 1 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
1 raises · 0 cuts · 0 unchanged · 3 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.